Clinical trial NCT06195813: Asparagus Capsule Consumption and Blood Sugar and Lipids and Oxidative Stress
Official title: Effects of Asparagus Capsule Consumption on Blood Sugar and Lipids and Oxidative Stress in Overweight and Obese Participants
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Asparagus Capsule Consumption
Lead sponsor: Burapha University
Sponsor class: OTHER
First posted: 2024-01-08
Enrollment: 44
Sex: ALL
Minimum age (years): 18
Maximum age (years): 59
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Participants were randomly divided into 2 groups consisting of 23 asparagus capsules and 21 placebo capsules groups.
Primary purpose: PREVENTION

Brief summary: Participants were 44 overweight and obese persons, male and female, age 18-59 years. Participants were divided into 2 groups consisting of 23 asparagus capsules and 21 placebo capsules groups. They received health screenings including history taking, mental health questionnaire, and vital signs, height and body weight, body composition, fat distribution measurements and oral glucose tolerance test. Then, a venipuncture was conducted to determine blood glucose, insulin, lipids malondialdehyde and protein carbonyl levels.

Detailed description: The study design was cross-sectional. Participants were 44 overweight and obese persons, male and female, age 18-59 years. Participants were divided into 2 groups consisting of 23 asparagus capsules and 21 placebo capsules groups. They received health screenings including history taking, mental health questionnaire, and vital signs, height and body weight, body composition, fat distribution measurements and oral glucose tolerance test. Then, a venipuncture was conducted to determine blood glucose, insulin, lipids malondialdehyde and protein carbonyl levels. Analysis of covariance was used to analyze parameters between groups and paired t-test was used to analyze parameters intra-group.

Eligibility criteria: Inclusion Criteria:

* Man or woman, aged between 18 to 59 years
* Body mass index more than 23 (Asian criteria)
* No history of hypertension, diabetes, cardiovascular disease, respiratory disease, endocrine disease, neuromuscular disease, musculoskeletal disease, liver disease, renal disease, immune disease, infectious disease, or cancer
* No regular intake of dietary supplements, i.e., vitamins, antioxidants
* No regular smokers or alcohol drinkers (\>2 times per week)
* Not sportman or regular exerciser (\>2 times per week or \>150 min per week)
* No food allergy, especially shoot

Exclusion Criteria:

- Current signs or symptoms of infection, i.e., fever, hyperpnea, dyspnea, and palpitations.

Primary outcomes:
measure: Level of body fat
timeFrame: Day 0 and end of 12 weeks
measure: Level of fat mass
timeFrame: Day 0 and end of 12 weeks
measure: Level of fat distribution
timeFrame: Day 0 and end of 12 weeks
measure: Concentration of blood glucose
timeFrame: Day 0 and end of 12 weeks
measure: Concentration of blood insulin
timeFrame: Day 0 and end of 12 weeks
measure: Concentrations of blood lipids
timeFrame: Day 0 and end of 12 weeks
measure: Concentration of blood malondialdehyde
timeFrame: Day 0 and end of 12 weeks
measure: Concentration of blood protein carbonyl
timeFrame: Day 0 and end of 12 weeks
Secondary outcomes:
measure: Concentrations of blood glucose from oral glucose tolerance test
timeFrame: At 0 minute before glucose consumption and at 30, 60, 90, 120 minutes after glucose consumption
Other outcomes:
Locations:
city: Mueang
country: Thailand
facility: Faculty of Allied Health Sciences, Burapha University
state: ChonBuri
Study officials:
affiliation: Burapha University
name: Piyapong Prasertsri, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References: